Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study

This publication has 11 references indexed in Scilit:

• Residual dysglycemia when at target HbA1c of 7% (53mmol/mol) in persons with type 2 diabetes
  Diabetes Research and Clinical Practice, 2014
• Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study
  Diabetes Therapy, 2014
• Adherence to Therapies in Patients with Type 2 Diabetes
  Diabetes Therapy, 2013
• Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study
  Diabetes & Metabolism, 2012
• Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial
  Diabetes, Obesity and Metabolism, 2010
• Sitagliptin
  Drugs, 2010
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial
  Diabetes, Obesity and Metabolism, 2007
• Importance of Observational Studies in Clinical Practice
  Clinical Therapeutics, 2007
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998
• Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
  Diabetes Care, 1998